Cisplatin + nintedanib + pemetrexed + placebo

Author: qtqb

August undefined, 2024

WebJul 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … WebA subsequent analysis of the available intent-to-treat population based on independent review data showed a PFS benefit for patients treated with nintedanib plus pemetrexed compared with placebo plus pemetrexed (median PFS of 4.4 months versus 3.6 months; hazard ratio [HR] of 0.83 with a 95% confidence interval [CI] of 0.70–0.99; P=0.04), but ...

Short report of a phase II trial of nintedanib in recurrent …

WebApr 1, 2024 · Request PDF On Apr 1, 2024, Antoinette J. Wozniak and others published Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) Find, read and cite all ... WebThis is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma. lahcen damou

Nintedanib in combination with pemetrexed and cisplatin …

WebJ Clin Oncol 31(23):2895–2902 CrossRef Paz-Ares LG et al (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. WebDec 4, 2014 · At least one dose reduction of nintedanib or placebo was required by 18.6% and 6.3% of patients in the nintedanib plus docetaxel and placebo plus docetaxel groups, respectively. Gastrointestinal AEs … WebJul 5, 2024 · Nintedanib, oral, triple angiokinase inhibitor of VEGFR, PDGFR, and FGFR, has been investigated in a phase II study randomizing patients who received first line pemetrexed-cisplatin between nintedanib or placebo. Recently, preliminary data were reported on the additional effect of nintedanib added to cisplatin/pemetrexed. jeklena pletenica

Lung Cancer, Not One Disease: Diverse Patients Need Personalized ...

Use of Nintedanib and Pirfenidone in Non–Idiopathic Pulmonary …

WebPatients were randomly assigned in a 1:1 ratio to receive nintedanib or placebo. Randomization was stratiﬁed by histology (epithelioid or biphasic). Treatment with … WebMay 30, 2024 · Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Anna K. Nowak. x. Anna K. Nowak. Search for articles by this author , Federica Grosso. x ... jeklene konstrukcijeWebPemetrexed (Alimta) is administered as 500 mg/m 2 as an intravenous infusion over 10 minutes after pembrolizumab and prior to carboplatin or cisplatin on day 1 of each 21-day cycle for 4 cycles for initial treatment of metastatic non-squamous NSCLC in individuals with a creatinine clearance of 45 mL/min or greater. lahcen brahim

"WebPatients received oral nintedanib (150 mg or 200 mg twice daily for 12 weeks) or placebo, in addition to usual neoadjuvant chemotherapy with intravenous gemcitabine 1000 mg/m 2 on days 1 and 8 and intravenous cisplatin 70 mg/m 2 on day 1 of a 3-weekly cycle. The primary endpoint was pathological complete response rate, assessed at cystectomy or ... " - Cisplatin + nintedanib + pemetrexed + placebo

Cisplatin + nintedanib + pemetrexed + placebo

Review of nintedanib plus pemetrexed/cisplatin in patients with ...

Weband safety of nintedanib versus placebo, each in combination with up to 6 cycles of pemetrexed/cisplatin, followed by nintedanib or placebo maintenance, in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM)4 In Phase II, nintedanib demonstrated an improvement in the primary WebNintedanib is an oral angiokinase inhibitor targeting multiple signaling pathways implicated in the pathogenesis of MPM, including the VEGF receptor. The phase III part of the …

Did you know?

WebApr 7, 2024 · This is a Phase II trial assessing the efficacy of nintedanib, an oral multi-targeted kinase inhibitor, in patients with recurrent malignant pleural mesothelioma. The drug was well tolerated but the activity was modest with no responses and 40% stable disease at 8 weeks. WebMay 15, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME …

WebApr 16, 2024 · Patients in the pembrolizumab-combination group received pemetrexed, a platinum-based drug, and pembrolizumab; those in the placebo-combination group received pemetrexed, a platinum-based … WebThe intervention group received up to six cycles of pemetrexed and cisplatin plus nintedanib 200 mg twice daily while the control group received chemotherapy plus …

WebDec 19, 2016 · ITT analysis of the primary end point showed that treatment with nintedanib plus pemetrexed resulted in a significant prolongation of PFS compared with placebo plus pemetrexed (4.4 vs. 3.6 months with a HR of 0.83 and a p value of 0.04). WebSep 18, 2024 · This study aims to evaluate the safety of nintedanib when used in combination with pemetrexed and cisplatin in patients with unresectable MPM. This randomized, double-blind, placebo-controlled, phase 3 trial included a total of 458 patients with unresectable epithelioid MPM.

WebApr 11, 2024 · Nintedanib doses were permitted to be reduced to 150 mg, 100 mg, or 50 mg (or to 100 mg or 50 mg for patients with GFR 40–60 mL/min). Both gemcitabine and …

WebJul 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … jeklenica 10mmWebJan 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2024; 7: 569-580 View in Article Scopus (84) PubMed Summary Full Text Full Text PDF Google Scholar Article Info jeklar tomažWebSep 11, 2024 · Treatment with pemetrexed and cisplatin and either nintedanib or matching placebo was given in 21-day courses. … lahcen daoudiWebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … jekl brnoWebMay 16, 2013 · This randomized, double-blinded study evaluated nintedanib – a triple angiokinase inhibitor – plus pemetrexed compared to pemetrexed plus placebo in patients with advanced non-squamous NSCLC not responding to, or who progressed after, first-line chemotherapy. 20 LUME-Lung 2 did not pass the pre-defined interim futility analysis from ... jeklenica 2mmWebThe pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) c… lahcene benahliaWebMar 27, 2024 · For unresectable MPM, a regimen of pemetrexed (Pem) and cisplatin (Cis) was approved as the standard of care in first-line treatment by the FDA in 2004 . Currently, numerous studies are being conducted to explore the efficacy of novel agents and regimens for MPM first-line treatment. ... Regardless, any kind of therapy other than placebo may … lahcene